Roche submits multiple sclerosis drug fenebrutinib to regulators despite patient deaths
By Patricia Weiss
Published on April 22, 2026.
Swiss drug manufacturer, Roche, has submitted its multiple sclerosis drug, fenebrutinib, to regulators despite seven deaths during studies. The company believes the overall benefit-risk profile of the drug is favourable and if regulatory authorities approve it, it will not replace its existing drug.
Related Articles
Asking Eric: High School bully moved back to our hometown. And - surprise - he’s still terrible
A high-profile bully, now known as a professional, has re-emerged in his hometown, seeking to reconnect with me via social media.
This Iconic Mall Retailer Quietly Closing Dozens Of Stores: See MI Locations
Bath & Body Works has closed nearly 100 stores as it retires from malls to focus on online distribution, aiming for increased sales.
This Iconic Mall Retailer Quietly Closing Dozens Of Stores: See GA Locations
Bath & Body Works has closed nearly 100 stores as it retires from malls to focus on online distribution, aiming for increased sales.